Homepage > Company > Media > Pharma News > 2018 > Europe recalls generic heart drug made in China on cancer fears

Europe recalls generic heart drug made in China on cancer fears

LONDON (Reuters) - A number of high blood pressure and heart drugs containing an ingredient made in China are being recalled across Europe after an impurity that may cause cancer was found in them, officials said on Thursday.

The European Medicines Agency said the recall followed identification of the impurity in the active substance valsartan manufactured by Zhejiang Huahai Pharmaceuticals, a company in Linhai, China.

Britain’s Medicines and Healthcare products Regulatory Agency said the appearance of the impurity - N-nitrosodimethylamine - came after a change in the process for making valsartan at one facility.

Valsartan was originally developed by Novartis and the Swiss company marketed it as Diovan, but it is now off patent and is used in a number of generic medicines.

European regulators said they were working together to investigate the extent of the issue.

Reuters could not immediately reach Zhejiang Huahai Pharmaceuticals for comment outside of regular business hours.

JULY 5, 2018

https://uk.reuters.com/

Read also

EC approves AstraZeneca’s Fasenra for EGPA treatment

The European Commission (EC) has approved AstraZeneca‘s Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangii...

Genprex reports positive preclinical gene therapy data

Genprex, Inc., a clinical-stage gene therapy company, announced positive preclinical results for its lead drug candidate, Reqorsa® (quratusugene ozeplasmid) Gene Therapy, at the recent EORTC-...

Astellas withdraws Europe ACP application for AMD treatment

Astellas Pharma has announced the withdrawal of its marketing authorisation application for IZERVAY (avacincaptad pegol, ACP) intravitreal solution to treat geographic atrophy (GA) sec...

New report demands greater understanding of the impact of change on academia

Digital Science, a technology company serving stakeholders across the research ecosystem, is today calling for greater awareness of the impact that a myriad of fast-developing technologies are having ...